Physician profile
James Robert Griffith
NPI 1376652412
$1,464.02
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,010 · 2022: $272 · 2023: $159 · 2024: $22.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $249.77 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $238.77 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $198.34 | 2021-2023 | Lifevest |
| Amgen INC. | $117.42 | 2021-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $100.36 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.86 | 2021-2023 | Jardiance |
| Abbott Laboratories | $84.27 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $81.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $64.85 | 2021-2022 | |
| Chiesi USA, INC. | $64.44 | 2021 | |
| Amarin Pharma, INC. | $50.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.24 | 2021 | |
| Novo Nordisk INC | $32.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.59 | 2021 | |
| Medtronic, INC. | $15.02 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amicus Therapeutics, INC. | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.